EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Prognostic Value of Baseline Neutrophil-to-Lymphocyte Ratio and Clinicopathological Factors in a Multicenter Cohort of Urothelial Carcinoma Treated With Adjuvant Nivolumab

Asuka Sano, Yuya Oishi, Gaku Ishikawa, Shunsuke Watanabe, Shinya Watanabe, Yoshihiro Tsuchiya, Ryoichi Maenosono, Yuki Yoshikawa, Kyosuke Nishio, Hirofumi Morinaka, Masanobu Saruta, Wataru Fukuokaya, Kyohei Watanabe, Hiromitsu Watanabe, Keita Tamura, Daisuke Motoyama, Takafumi Yanagisawa, Kiyoshi Takahara, Yutaka Yamamoto, Kazutoshi Fujita, Teruo Inamoto

Urologia Internationalis · 2026-10-05 · 1-1

DOI: 10.1159/uin/aewag032 ↗
AbstractBibliografische Angaben

Abstract

Introduction: Adjuvant nivolumab prolongs disease-free survival (DFS) after radical surgery for high-risk urothelial carcinoma (UC), yet recurrence remains common. We investigated the prognostic impact of clinical and systemic inflammatory factors in these patients. Methods: We retrospectively analyzed 127 patients who received adjuvant nivolumab following radical surgery at six institutions between April 2022 and January 2026. Prognostic factors for DFS were evaluated using Cox proportional hazards regression models. Results: The median follow-up was 12.0 months, and DFS events occurred in 43.3% of patients. In the multivariable analysis, advanced pathological T stage (pT3–4 vs. pT1–2) (hazard ratio [HR], 2.525; 95% CI, 1.067–5.979) and baseline neutrophil-to-lymphocyte ratio (NLR) (HR, 1.216 per 1 unit increase; 95% CI, 1.034–1.430; p = 0.018) emerged as independent predictors of inferior DFS. Additionally, female sex showed an independent association with shorter DFS (HR, 0.275; 95% CI, 0.152–0.495; p < 0.001, though this finding warrants cautious interpretation given baseline characteristics and the small proportion of female patients. Conclusion: Baseline NLR and advanced pT stage serve as valuable independent prognostic factors for patients receiving adjuvant nivolumab. Although interpreted with caution regarding specific subgroups and retrospective limitations, these findings highlight key risk factors in this setting and provide a rationale for larger prospective validation.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →